{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:13:12Z","timestamp":1757628792321,"version":"3.44.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,10]]},"DOI":"10.7759\/cureus.91965","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:17:23Z","timestamp":1757503043000},"source":"Crossref","is-referenced-by-count":0,"title":["STOP-CINV Study: Safety and Efficacy of IV Akynzeo\u00ae (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients"],"prefix":"10.7759","author":[{"given":"Pragya","family":"Shukla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaunak","family":"Valame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naval K","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinandan","family":"Hanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amullya","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiprasad","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup U","family":"Petare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Bhushan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanmant","family":"Barkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0872","article-title":"Preventing chemotherapy-induced nausea and vomiting with netupitant\/palonosetron, the first fixed combination antiemetic: current and future perspective","volume":"15","author":"Aapro M","year":"2019","unstructured":"Aapro M, Zhang L, Yennu S, LeBlanc TW, Schwartzberg L. Preventing chemotherapy-induced nausea and vomiting with netupitant\/palonosetron, the first fixed combination antiemetic: current and future perspective. Future Oncol. 2019, 15:1067-84. 10.2217\/fon-2018-0872","journal-title":"Future Oncol"},{"key":"ref2","article-title":"Advances in the management of chemotherapy-induced nausea and vomiting: new data from recent and ongoing trials","volume":"13","author":"Roeland E","year":"2015","unstructured":"Roeland E, Aapro MS, Schwartzberg LS. Advances in the management of chemotherapy-induced nausea and vomiting: new data from recent and ongoing trials. Clin Adv Hematol Oncol. 2015, 13:1-14.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02474-5","article-title":"Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective","volume":"40","author":"Abe M","year":"2023","unstructured":"Abe M, Iihara H, Aogi K. Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective. Adv Ther. 2023, 40:1913-25. 10.1007\/s12325-023-02474-5","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4131-3","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro M","year":"2018","unstructured":"Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018, 26:5-9. 10.1007\/s00520-018-4131-3","journal-title":"Support Care Cancer"},{"key":"ref6","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel N","year":"2017","unstructured":"Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017, 23:S259-65.","journal-title":"Am J Manag Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00019","article-title":"Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management","volume":"8","author":"Rapoport BL","year":"2017","unstructured":"Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol. 2017, 8:19. 10.3389\/fphar.2017.00019","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-78665-0_50","article-title":"The burden of chemotherapy induced nausea and vomiting on patients\u2019 daily lives: Italian perspectives","author":"Ballatori E","year":"2010","unstructured":"Ballatori E, Roila F, Ruggeri B, Bruno AA, Tiberti S, di Orio F. The burden of chemotherapy induced nausea and vomiting on patients\u2019 daily lives: Italian perspectives. Handbook of Disease Burdens and Quality of Life Measures. Preedy VR, Watson RR (ed): Springer, New York, NY; 2010. 10.1007\/978-0-387-78665-0_50"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03554-1","article-title":"Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China","volume":"147","author":"Sun Y","year":"2021","unstructured":"Sun Y, Zheng Y, Yang X, et al.. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China. J Cancer Res Clin Oncol. 2021, 147:2701-8. 10.1007\/s00432-021-03554-1","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07978-y","article-title":"Prevalence and predictors of long-delayed (>\u2009120 h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow R","year":"2023","unstructured":"Chow R, Yin LB, Baqri W, et al.. Prevalence and predictors of long-delayed (>\u2009120 h) chemotherapy-induced nausea and vomiting (CINV)\u2014a systematic review and individual patient data meta-analysis. Support Care Cancer. 2023, 31:505. 10.1007\/s00520-023-07978-y","journal-title":"Support Care Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0527","article-title":"Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy","volume":"25","author":"Schwartzberg L","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, et al.. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020, 25:e589-97. 10.1634\/theoncologist.2019-0527","journal-title":"Oncologist"},{"key":"ref12","unstructured":"List of new drugs approved in year 2018. https.\/\/cdsco.gov.in\/opencms\/resources\/UploadCDSCOWeb\/2018\/UploadApprovalNewDrugs\/latesnd18approval.pdf."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.01.028","article-title":"Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea\/emesis registry in oncology (NERO)","volume":"166","author":"Aapro M","year":"2022","unstructured":"Aapro M, Caprariu Z, Chilingirov P, et al.. Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea\/emesis registry in oncology (NERO). Eur J Cancer. 2022, 166:126-33. 10.1016\/j.ejca.2022.01.028","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103143","article-title":"Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: a review of phase 3 studies","volume":"157","author":"Aapro M","year":"2021","unstructured":"Aapro M, Navari RM, Roeland E, Zhang L, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: a review of phase 3 studies. Crit Rev Oncol Hematol. 2021, 157:103143. 10.1016\/j.critrevonc.2020.103143","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03378","article-title":"Errata","volume":"39","year":"2021","unstructured":"Errata. J Clin Oncol. 2021, 39.96. 10.1200\/JCO.20.03378","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3405-x","article-title":"Erratum to: 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Roila F","year":"2017","unstructured":"Roila F, Warr D, Hesketh PJ, et al.. Erratum to: 2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following moderately emetogenic chemotherapy. Support Care Cancer. 2017, 25:295-6. 10.1007\/s00520-016-3405-x","journal-title":"Support Care Cancer"},{"key":"ref17","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). antiemesis (version 1.2021). https:\/\/www.nccn.org."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice","volume":"22","author":"Aapro M","year":"2022","unstructured":"Aapro M, Jordan K, Scott\u00e9 F, Celio L, Karthaus M, Roeland E. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets. 2022, 22:806-24. 10.2174\/1568009622666220513094352","journal-title":"Curr Cancer Drug Targets"},{"key":"ref19","unstructured":"Akynzeo\u00ae US Prescribing Information. Accessed. August 13, 2025: https:\/\/www.akynzeo.com\/assets\/pdf\/Akynzeo-USPI.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34088","article-title":"A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC","volume":"128","author":"Matsuura K","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K, et al.. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022, 128:1692-8. 10.1002\/cncr.34088","journal-title":"Cancer"},{"key":"ref21","article-title":"Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens","volume":"35","author":"Fujii T","year":"2015","unstructured":"Fujii T, Nishimura N, Urayama KY, et al.. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens. Anticancer Res. 2015, 35:379-83.","journal-title":"Anticancer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata A","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, et al.. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022, 40:180-8. 10.1200\/JCO.21.01315","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy169","article-title":"Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy","volume":"29","author":"Schwartzberg L","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, et al.. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018, 29:1535-40. 10.1093\/annonc\/mdy169","journal-title":"Ann Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29094","article-title":"The effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in patients with multiple risk factors for chemotherapy-induced nausea and vomiting: a multicenter, observational indian study","volume":"14","author":"Vaswani B","year":"2022","unstructured":"Vaswani B, Dattatreya PS, Barkate H, Bhagat SB, Patil S, Jadhav AY. The effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in patients with multiple risk factors for chemotherapy-induced nausea and vomiting: a multicenter, observational indian study. Cureus. 2022, 14:e29094. 10.7759\/cureus.29094","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.606","article-title":"Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India","volume":"11","author":"Vaswani B","year":"2020","unstructured":"Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India. World J Clin Oncol. 2020, 11:606-13. 10.5306\/wjco.v11.i8.606","journal-title":"World J Clin Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients","volume":"9","author":"Kaushal P","year":"2015","unstructured":"Kaushal P, Atri R, Soni A, Kaushal V. Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience. 2015, 9:567. 10.3332\/ecancer.2015.567","journal-title":"Ecancermedicalscience"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.123580","article-title":"A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis","volume":"50","author":"Maru A","year":"2013","unstructured":"Maru A, Gangadharan VP, Desai CJ, Mohapatra RK, Carides AD. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Indian J Cancer. 2013, 50:285-91. 10.4103\/0019-509X.123580","journal-title":"Indian J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/407123-stop-cinv-study-safety-and-efficacy-of-iv-akynzeo-fosnetupitant-235-mg-and-palonosetron-025-mg-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-indian-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:17:25Z","timestamp":1757503045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/407123-stop-cinv-study-safety-and-efficacy-of-iv-akynzeo-fosnetupitant-235-mg-and-palonosetron-025-mg-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-indian-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.91965","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}